glp 1 agonist effects The cardiovascular of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action Potential Use of GLP-1 and

Efficacy and safety of polyethylene glycol loxenatide monotherapy in type 2 diabetes patients: A multicentre, randomized, double-blind, placebo-controlled phase 3a clinical trial

Future research must prioritize rigorous translational frameworks that integrate molecular, neurophysiological, and behavioral data across species

Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease

Additionally, these GLP-1 RAs have been explored as an effective means of weight loss, with the STEP clinical trials showing a mean of 5% weight loss at the end of 68 weeks of treatment

Back Diem, P, Ducluzeau, PH, Scheen, A (Jan-March 2022) 'The discovery of insulin', Diabetes, Epidemiology and Management , 5, 100049